SCHEMBL4246536

SCHEMBL4246536

COc1ccc(-c2cc(-c3ccc4[nH]ncc4c3)nc(=O)[nH]2)cc1OC

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 9/20 0.67
MAPK13 O15264 1/20 0.67
DAPK3 O43293 1/20 0.67
ROCK2 O75116 1/20 0.67
PRKD3 O94806 1/20 0.67
MAP4K4 O95819 1/20 0.67
CDK1 P06493 1/20 0.67
PIM1 P11309 1/20 0.67
FGFR1 P11362 1/20 0.67
RPS6KB1 P23443 1/20 0.67
CDK2 P24941 1/20 0.67
MAPK1 P28482 1/20 0.67
FLT4 P35916 1/20 0.67
CSNK1A1 P48729 1/20 0.67
CSNK1D P48730 1/20 0.67
MAPKAPK2 P49137 1/20 0.67
CLK2 P49760 1/20 0.67
GSK3A P49840 1/20 0.67
GSK3B P49841 1/20 0.67
IRAK1 P51617 1/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4252049 0.90 CDC7 (0.67) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL4239214 0.85 CDC7 (0.60) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL385584 0.81 CDC7 (1.00) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL4245493 0.79 CDC7 (1.00) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL19782373 0.78 CXCL12 (0.72) CDC7CXCL12KDM4E
SCHEMBL4241465 0.78 CDC7 (1.00) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL4243686 0.78 CDC7 (1.00) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL4243697 0.78 CDC7 (0.70) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL4240964 0.77 CDC7 (0.82) CDC7MAPK13DAPK3ROCK2PRKD3
SCHEMBL385150 0.77 CDC7 (0.68) CDC7PIM1MAPK1GSK3BCSNK2A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010521-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 Novartis Ag (CH) 2009-01-07 EP claimed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US claimed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO claimed
EP-2010521-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 Novartis Ag (CH) 2009-01-07 EP disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 CDC7, CDC37, CDC73 CDC7 1/4885MAPK13 2059/4885DAPK3 1071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.